← All Posts
PTC
PTC Therapeutics, Inc.
June 03, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
To elect the four Class I director nominees nominated by our Board of Directors and named in the proxy statement, each to serve for a term ending in 2029, or until his or her successor has been duly elected and qualified; |
|
| 1.1 |
Jessica Chutter |
✓ For(420.392)
|
| 1.2 |
Matthew B. Klein, M.D., M.S., F.A.C.S. |
Withhold(420.392)
|
| 1.3 |
Stephanie S. Okey, M.S. |
✓ For(420.392)
|
| 1.4 |
Jerome B. Zeldis, M.D., Ph.D. |
✓ For(420.392)
|
| 2 |
To ratify the appointment of Ernst & Young LLP, a registered public accounting firm, as our independent registered public accounting firm for the fiscal year ending December 31, 2026; |
✓ For(420.392)
|
| 3 |
To hold an advisory vote to approve named executive officer compensation; |
✓ For(420.392)
|
| 4 |
To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. |
Informational(420.392)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial